


Midas



[CEO](#) — [NEWS](#) — [PSYCHEDELICS](#) — [RECOMMENDED](#) — [VIDEOS](#)

A New Vaccine Against Depression? | MYND Life Sciences

By [MIDASLETTER LIVE](#) | JULY 1, 2021

Watch

Midas



Midas



0:00 / 0:00

DOWNLOAD FILE | PLAY IN NEW WINDOW | SUBSCRIBE: ITUNES | SPOTIFY

MYND Life Sciences (**CNSX:MYND**) is a company exploring anti-inflammatory benefits of psilocybin and other psychedelic compounds as they apply to depression and other central nervous system (CNS) disorders.

There have been a lot of breakthroughs over the last decade defining what causes depression. Historically, depression has been diagnosed based on a checklist of symptoms system. It is now theory that depression can be looked at as neuro-inflammation. MYND has been concentrating on how psychedelics scientifically affect the brain and can be used as an anti-inflammatory for the last decade. The research already carried out suggests that psilocybin and psychedelic analogs can be used to treat this inflammation and ultimately depression as a whole.

“Just signed a licensing agreement for, get this? A vaccine against depression, against the inflammatory process. A little bit Star Trek-ish, but on the other hand when you have a physical cause, that’s where we are in health care in 2021.” – MYND Life Sciences CEO Dr. Lyle Oberg

MYND is currently driving toward the initiation of up to six clinical trials on the efficacy of psilocybin and psilocybin analogs by the end of this year. These clinical trials are looking into sepsis, cytokine storm, depression, and biomarkers. MYND expects to be revenue-generating and have a drug available to the public by the middle of next year.

Watch the full interview to learn about MYND’s 4 patents, its Section J exemptions studying 38 different psychedelic analogs, its work with the FDA/Health Canada, and its projected pathway to

Midas

00:00 – MYND Life Sciences CEO Dr Lyle Oberg

00:37 – MYND Life Sciences overview

02:29 – Psychedelic research

04:04 – Clinical trials

05:49 – Timeline until treatments are available to patients

06:34 – Pathway to revenue

08:25 – Regulatory environment changes

10:01 – Publishing research



SIGN UP TO OUR NEWSLETTER

Get financial news right in your inbox.

SUBSCRIBE NOW ➔ **MidasLetter**

Related Articles



MidasLetter
RAW


**DISRUPTIVE TECHNOLOGY
BRINGING DIAGNOSTICS
TO THE HOME**

Midas

CEO - NEWS - RECOMMENDED - TECHNOLOGY - VIDEOS

Disruptive Technology Bringing Diagnostics to the Home | Health Logic (CHIP.H)

MIDASLETTER LIVE | JUNE 30, 2021



CEO - INTERVIEW - PSYCHEDELICS - RECOMMENDED - VIDEOS

Psychedelic Medicine Treating Addiction | Awakn Life Sciences (AWKN)

MIDASLETTER LIVE | JUNE 28, 2021



Midas

CEO - CRYPTO - FINTECH - NEWS - RECOMMENDED - TECHNOLOGY - VIDEOS

Kevin O'Leary Moves into Decentralized Finance with WonderFi

MIDASLETTER LIVE | JUNE 21, 2021



CEO - INTERVIEW - NEWS - REAL ESTATE - RECOMMENDED - TECHNOLOGY - VIDEOS

Voxtur Analytics (VXTRF) Achieves 183% Revenue Growth YoY

MIDASLETTER LIVE | JUNE 3, 2021

JAMES WEST'S

MidasLetter

DISCLOSURE

Cannabis Newswire Provided by Cision - Insights covering all aspects of the cannabis sector.

[VIEW NEWswire BY CISION](#)**Most Shared**<https://midasletter.com/2021/07/a-new-vaccine-against-depression-mynd-life-sciences/>

Midas



A New Vaccine Against Depression? | MYND Life Sciences...

3 Psychedelic Stocks Getting High Right Now | Midas Letter RAW ft ATAI, FTRP, DRUG, Wolf Street...

New NASDAQ Psychedelic Stock is an IP Giant | Atai Life Sciences...

MIDAS LETTER'S EMERGING COMPANY ORIENTATION

Generate outsized returns among emerging companies that can light upon 1,000 percent gains.

[SEE CHOSEN PICKS TO DATE](#) ➔



Follow

YOUTUBE 

TWITTER 

INSTAGRAM 

LINKEDIN 

FACEBOOK 

Midas



1749 NE Miami Ct #507

Miami, FL 33132

+1 (904) 404-8873

[Terms of Service](#)

[Privacy Policy](#)

[Videos](#)

[Podcasts](#)

[News](#)

[Commentary](#)

Cannabis Newswire provided by Cision

Copyright ©2020 Midas Letter | All Rights Reserved